Concord Imaging Center News & Links
New 3D Mammography at Concord Imaging offers better chance to diagnose breast cancer earlier, at more treatable stages
Concord Imaging is excited to offer 3D mammography (breast tomosynthesis) for breast cancer screening. Breast tomosynthesis produces a three-dimensional view of the breast tissue that helps radiologists identify and characterize individual breast structures without the confusion of overlapping tissue.
The center’s Selenia® Dimensions® breast tomosynthesis system is made by Hologic, a world leader in digital mammography. The Selenia Dimensions system offers exceptionally sharp breast images, an advanced ergonomic design providing more patient comfort, and the ground-breaking tomosynthesis platform designed to deliver superior screening and diagnostic performance for all breast types. 1
We believe breast tomosynthesis will benefit all screening and diagnostic mammography patients, and is especially valuable for women receiving a baseline screening, those who have dense breast tissue and/or women with a personal history of breast cancer.
Breast cancer screening with tomosynthesis when combined with a conventional 2D mammography has a 40% higher invasive cancer detection rate than conventional 2D mammography alone.2-4 Tomosynthesis technology gives radiologists increased confidence with up to a 40% reduction in recall rates. 4-5
The tomosynthesis screening experience is similar to a traditional mammogram. During a tomosynthesis exam, multiple, low-dose images of the breast are acquired at different angles. These images are then used to produce a series of one-millimeter thick slices that can be viewed as a 3D reconstruction of the breast.
By offering women the latest and more accurate6 technology in mammography, Concord Imaging expects to increase the number of area women who will be routinely screened. Breast cancer is the second leading cause of cancer death among women, exceeded only by lung cancer. Statistics indicate that one in eight women will develop breast cancer sometime in her lifetime. The stage at which breast cancer is detected influences a woman’s chance of survival. If detected early, the five-year survival rate is 98 percent. 7
Concord Imaging is committed to the fight against breast cancer. In offering breast tomosynthesis digital mammography, Concord Imaging provides the latest in imaging technology. Tomosynthesis (3D Mammography) is now available at Concord Imaging. If you would like to schedule a mammogram or have questions about this important breast health procedure, please contact Scheduling at 210-572-2222.
1 Rafferty E, Park J, Philpotts L, et al. “Assessing Radiologist Performance Using Combined Digital Mammography and Breast Tomosynthesis Compared with Digital Mammography Alone: Results of a Multicenter, Multireader Trial.” Radiology. 2013 Jan; 266(1):104-13. Epub 2012 Nov 20.
2 Skaane P, Bandos A, Gullien R, et al. “Comparison of Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a Population-based Screening Program.” Radiology. 2013 Apr; 267(1):47-56. Epub 2013 Jan 7.
3 Ciatto S, Houssami N, Bernardi D, et al. “Integration of 3D Digital Mammography with Tomosynthesis for Population Breast-Cancer Screening (STORM): A Prospective Comparison Study” The Lancet Oncology. 2013 Jun;14(7):583-589. Epub 2013 Apr 25.
4 Rose S, Tidwell A, Bujnock L, et al. “Implementation of Breast Tomosynthesis in a Routine Screening Practice: An Observational Study.” American Journal of Roentengenology. 2013 Jun; 200(6): 1401-1408. Epub 2013 May 22.
5 Haas B, Kalra V, Geisel, J et al. “Comparison of Tomosynthesis Plus Digital Mammography and Digital Mammography Alone for Breast Cancer Screening.” Radiology. 2013 Jul 30. [Epub ahead of print].
6Zuley M, Bandos A, Ganott M, et al. “Digital Breast Tomosynthesis versus Supplemental Diagnostic Mammographic Views for Evaluation of Noncalcified Breast Lesions.” Radiology. 2013 Jan; 266(1):89-95. Epub 2012 Nov 9.
7 Breast Cancer Facts & Figures 2011, American Cancer Society.
3D Mammography Videos
Amyvid for Alzheimer’s Offered
Amyvid (Florbetapir F 18 Injection) is a newly FDA-approved agent used to estimate the amount of amyloid plaque in the brain of patients with decline in mental function who are being evaluated for the diagnosis of Alzheimer’s disease. After injection of Amyvid, a PET scan of the brain is obtained which demonstrates areas where beta amyloid plaque, which is associated with Alzheimer’s disease, is deposited. This can be helpful to physicians in either excluding or making the diagnosis of Alheimer’s dementia. Unfortunately, at this time , no insurances cover payment for this exam so it is only performed on a cash basis at the time of service.
Digital Wireless Xray Unit in Texas!
Concord Imaging is pleased to announce the installation of the Carestream DRX-1 System at their Creekside location for performing Digital Radiography. Most current radiology facilities use Computed Radiography (CR) for performing radiographs (traditional “X-rays”). CR replaced the old system of Xray film in cassettes that had to be run through a processor. The CR systems still have to use a laser light to “read” the xray image on a cassette and this takes about 60 seconds per image.
Concord Imaging at Creekside has added the latest in state of the art technology to their Xray capabilities. With the new Carestream DRX-1 system, an all-digital detector plate is placed behind the area to be imaged and the xray exposure is taken in the conventional manner. From this point forward, the information is transmitted digitally in just a few seconds from the digital detector to the console and the image is ready to be sent to the PACS system where it is stored and can be interpreted by the radiologist. The image is transmitted and the technologist is ready to position the patient for the next exposure in a matter of seconds rather than minutes.
From a patient and referring office perspective, this allows Concord Imaging at Creekside to perform Xray exams in much less time than any other facility. This should translate into shorter exams for patients and less waiting time to get into the exam room.
“We began to look at areas in our facility where we potentially experience backlogs and Xray and Ultrasound were identified as areas where we sometimes had patients waiting longer than desirable or difficulty scheduling,” said Concord Imaging founder and radiologist Jeremy Wiersig, M.D. (Please see Ultrasound News). “We pride ourselves on our service and taking good care of patients, so when we learned about the DRX-1 Wireless DR system, we started investigating it, “ We thought we could make a real difference in patient wait and exam times and it’s really proving to be true. And the image quality is really spectacular.”
Come experience the 1st wireless Digital Radiography system in Texas at Concord Imaging the next time you need “Xrays”.
American Cancer Society Announces New Recommendations for MRI in Breast Cancer – New Guidelines for MRI screening for breast cancer in high risk women.
- Local staging of breast cancer: In patients with biopsy- proven malignancy, breast MRI is used to determine extent of disease (multifocality and multicentricity) in the ipsi-lateral breast and to screen for disease in the asymptomatic contra-lateral breast.
- Neoadjuvant chemotherapy: MRI is used before and during the course of chemotherapy to evaluate chemotherapeutic response and extent of residual disease prior to surgical treatment.
- Post-lumpectomy bed evaluation/scar vs. recurrence: MRI is applied in patients with prior lumpectomy and questionable recurrence within the lumpectomy bed on mammography and ultrasound.
- Positive margins post lumpectomy: MRI is used to assess the extent of residual disease in patients with close or positive margins post-lumpectomy. MRI can help determine if re-excision or mastectomy will be necessary.
- Chest wall invasion: MRI is indicated for the evaluation of chest wall involvement prior to lumpectomy or mastectomy.
- Occult primary: In patients presenting with axillary lymphadenopathy and no mammographic evidence of malignancy, MRI is utilized to assess for an occult primary.
- Palpable lump: In patients with a palpable lump and a negative diagnostic evaluation on mammography and sonography, MRI may be useful to exclude an underlying abnormality.
- Problem-solving/difficult mammogram: MRI may be used as a problem-solving tool in the situation of a difficult mammogram.
- Screening of high-risk patients: Screening MRI is now recommended by the ACS for women with an approximate 20 percent to 25 percent or greater lifetime risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women treated for Hodgkin’s disease.
- Implant integrity: Non-contrasted MRI using silicone-sensitive sequences is used to assess implant integrity (intra- and extra-capsular implant rupture).
|National Cancer Institute – Learn about Digital vs. Film Mammography
Digital Mammography Trial Results Announced: Learn more about Women with Dense Breasts, Women Younger than 50, and Those Who are Perimenopausal May Benefit from Digital Mammograms
Alzheimer’s Disease and PET Scans
Charlton Heston Speaks Out
Charlton Heston knows first hand that detecting Alzheimer’s Disease early gives patients extended quality time with loved ones. Heston announced in 2002 that he had been diagnosed with Alzheimer’s after a PET scan detected signs of the disease.
UCLA researchers have found that PET scans enable physicians to diagnose Alzheimer’s before the symptoms set in, which gives patients options to help delay the progression of the disease.
Using PET to determine if patients have Alzheimer’s would correspond to a 65% decrease in avoidable months of nursing home care, and a 48% drop in unnecessary drug treatment, according to Dr. Daniel Silverman, assistant professor of molecular and medical pharmacology and associate director of imaging for the UCLA Alzheimer’s Disease Center.
“Even a 6-month difference in the date of detection can profoundly affect the progression of Alzheimer’s,” said Dr. Michael E. Phelps, chair of the Department of Molecular Medical Pharmacology at the David Geffen School of Medicine at UCLA.
PET scans offer Alzheimer’s patients HOPE.
- Charlton Heston advocates the benefits of PET for early Alzheimer’s Detection (public service announcement from the Academy of Molecular Imaging): >>More
- Medicare approves PET in Alzheimer’s disease. The Centers for Medicare and Medicaid Services (CMS) announced September 15, 2004 that it will provide limited coverage for the use of FDG-PET in the diagnosis and treatment of mild cognitive impairment (MCI) and early dementia in elderly patients meeting certain criteria: >>More
- Alzheimer’s Foundation of America Supports Medicare Reimbursement for Brain Scans.
Press Release announcing the organization’s support of the federal government’s proposal to provide Medicare reimbursement of PET for some individuals with suspected Alzheimer’s disease. >>More.
- Made in Her Mother’s Image? article from USAToday.com: “Experimental Brain scans may show Alzheimer’s in her future, or not.” >>More